2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Plasminogen/Plasmin
  5. Plasminogen/Plasmin Inhibitor

Plasminogen/Plasmin Inhibitor

Plasminogen/Plasmin Inhibitors (6):

Cat. No. Product Name Effect Purity
  • HY-B0236
    6-Aminocaproic acid
    		Inhibitor 99.86%
    6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders.
  • HY-185319A
    Pexamsiran sodium
    		Inhibitor
    Pexamsiran sodium is a siRNA that inhibits plasminogen synthesis reducer, and can be use for the study of hereditary haemorrhagic telangiectasia.
  • HY-182600
    KLK6-IN-1
    		Inhibitor
    KLK6-IN-1 is a reversible small‑molecule inhibitor of KLK6, KLK1, and plasmin. KLK6-IN-1 shows IC50 values of 1.57 μM (KLK6), 5.1 μM (KLK1), 7.4 μM (plasmin), and Ki values of 0.8 μM (KLK6), 2.4 μM (KLK1), 1.3 μM (plasmin). KLK6-IN-1 is highly selective for KLK6 and its proteolytic network. KLK6-IN-1 induces oligodendrocyte differentiation by promoting oligodendrocyte precursor cell maturation. KLK6-IN-1 can be used for the research of multiple sclerosis.
  • HY-185319
    Pexamsiran
    		Inhibitor
    Pexamsiran is a siRNA that inhibits plasminogen synthesis, and can be use for the study of hereditary haemorrhagic telangiectasia.
  • HY-182565
    PSI-112
    		Inhibitor
    PSI-112 is a YO-class μPlm inhibitor, with IC50 values of 0.38 μM, 1.48 μM and 0.37 μM against the wild-type, F587A mutant and K607A mutant, respectively. PSI-112 shows low affinity for uPA. PSI-112 can be used in cancer research.
  • HY-183860
    Pefabloc PL
    		Inhibitor
    Pefabloc PL is a plasmin inhibitor with submicromolar-range inhibitory activity against the trypsin-like serine protease plasmin.